

SCIENCE
The right
activation
of the right
T cells.
An important biological discovery expands horizons for cancer treatment
Marengo is taking an entirely different approach to improving patients’ T cell responses to cancer and tackling the shortcomings of current immuno-oncology (IO) therapies. Existing IO therapies have transformed cancer care, yet often are unable to overcome the dysfunctional T cell responses that develop in patients during cancer treatment. Currently, less than one-third of patients experience a durable response to existing treatments.




anti-Vβ antibodies
mimics natural modes of
TCR activation
mimics natural modes of
TCR activation
Our approach mimics natural, non-antigenic mechanisms of TCR activation, such as bacterial superantigen-induced TCR activation, with the flexible and convenient properties associated with therapeutic antibody platforms.
Normal in cancer: Antigen-specific TCR activation

Canonical bacterial TCR activation pathway

Marengo Therapeutics
TCR Activation
TCR Activation



Activating & Expanding Subsets of Vβ Through Direct Activation of the TCR
Through our unique TCR binding mechanism, our antibodies activate and gradually expand specific Vβ T cell subsets with exquisite selectivity. These Vβ T cells adopt a novel effector memory phenotype and efficiently traffic to tumor sites.






Marengo’s Selective T Cell Activation Repertoire (STAR) Bi-Specific Platform
Our powerful, proprietary STAR platform builds additional functionality and targeting arms onto our foundational Vβ T cell activation platform to further “tune” Vβ T cell responses to treat a range of refractory cancers.


KEY FEATURES
We are developing potent Vβ-based therapeutics with highly desirable features for clinical-ready assets.


1 Potent Efficacy
- Potent single-agent antitumor activity
- Rapid expansion of activated CD8 + CD4 Vβ T cells (< 5 days)
- Central memory reprogramming results in non-exhausted tumor infiltrating T cells
2 Durable Memory
- Memory effector Vβ T cells drive long-term durability / tumor immunity
3 Improved Safety
- Vβ variant activates <10% of the T cell compartment
- Less pro-inflammatory cytokines
- Regulatory T cells unaffected
1 Potent Efficacy
- Potent single-agent antitumor activity
- Rapid expansion of activated CD8 + CD4 Vβ T cells (< 5 days)
- Central memory reprogramming results in non-exhausted tumor infiltrating T cells
2 Durable Memory
- Memory effector Vβ T cells drive long-term durability / tumor immunity
3 Improved Safety
- Vβ variant activates <10% of the T cell compartment
- Less pro-inflammatory cytokines
- Regulatory T cells unaffected
FLEXIBLE DESIGN
We are building purposeful molecules with the right utility. Our approach engineers diverse T cell functionality with different co-stimulatory signals and targets specific Vβ variants for different therapeutic needs.

